Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 72-73 , January 2010

Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence

References 

  1. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardio metabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811–822
  2. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the framingham offspring study—implications for LDL management. J Clin Lipidol. 2007;1:583–592
  3. Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005;45:1611–1619
  4. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–1844

PII: S1933-2874(10)00002-4

doi: 10.1016/j.jacl.2010.01.001

Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 72-73 , January 2010

Article Tools